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Efficacy and safety of TTS fentanyl given directly after tramadol to patients
with cancer related pain (based on FEN-POL-2 trial)
Jacek ¸uczak1, Lidia Gorzeliƒska1, Rodryg Ramlau2,
Marek Wojtukiewicz3, Piotr Koralewski4, Maciej Krzakowski5, Jerzy Za∏uski6
The main purpose of the trial was to investigate the clinical efficacy and safety of TTS fentanyl administered over 28 days to
patients naive to strong opioids, treated over the past 3 days prior to entering the study with the maximal (400 mg) daily do-
se of tramadol. Seventy two patients were included in the study, all of them suffering from advanced cancer- related pain. All
patients started with the lowest availabe dose of fentanyl (delivery rate 25 µg/hr . If analgesia was insufficient, the patients we-
re given a strong opioid (5 mg of immediate-release oral morphine) or a non- opioid analgesic as 'rescue' medication. Pain in-
tensity was evaluated by means of the Visual Analoque Scale (VAS) and the Verbal Rating Scale (VRS). Sixty four patients we-
re eligible for analysis. During the study 18 patients continued with 25 µg/hr, and the remaining was administered a higher do-
se. The maximum dose was 150 µg/hr (2 patients). At the termination of the trial 45/64 (72%) patients had no pain or slight
pain, 15/64 (22%) had moderate pain and 4/64 (6%) experienced strong or very strong pain (VRS). At the end of the trial in
51/64 (79%) pts pain control was good to excellent (in an overall assesment of pain treatment). Clinically relevant respirato-
ry depression was not observed. The following side effects of opioids were observed: nausea(N=3), vomiting (N=3), consti-
pation (N=2) and sweating (N=1). Transdermal fentanyl proved to be an effective and safe analgesic in the treatment of can-
cer- related pain in patients naive to strong opioids.
Ocena efektywnoÊci i bezpieczeƒstwa stosowania TTS fentanylu bezpoÊrednio po tramadolu, 
u pacjentów z bólem pochodzenia nowotworowego (na podstawie badania FEN-POL-2 trial)
Celem badania by∏a ocena skutecznoÊci i bezpieczeƒstwa stosowania TTS fentanylu u chorych z bólem nowotworowym, któ-
rzy poprzednio nie otrzymywali silnych opioidów. Do badania w∏àczono 72 pacjentów, leczonych przez ostatnie 3 dni trama-
dolem w dawce 400 mg na dob´ z niedostatecznym efektem przeciwbólowym. Nat´˝enie bólu oceniano za pomocà Wizual-
nej Skali Analogowej (VAS) oraz S∏ownej Skali Oceny Bólu (VRS). U wszystkich badanych stosowanie TTS fentanylu roz-
pocz´to od dawki 25 µg/godz., a w razie wystàpienia bólu przebijajàcego podawano 5 mg roztworu wodnego szybko dzia∏ajàcej
morfiny lub nie opioidowe leki przeciwbólowe. Podczas badania dawk´ poczàtkowà TTS fentanylu utrzymano u 18 chorych,
pozostali wymagali zwi´kszenia dawek. Maksymalna dawka wynosi∏a 150 µg/godz. i by∏a stosowana u 2 pacjentów. Trwajà-
ce 28 dni badanie ukoƒczy∏o 64 chorych. W ostatnim dniu badania 45/64 (72%) chorych zg∏asza∏o brak bólu lub ból o nie-
znacznym nasileniu, 15/64 (22%) ból o Êrednim nat´˝eniu, a 4/64 (6%) ból silny lub bardzo silny wg VRS. W trakcie bada-
nia wystàpi∏y nast´pujàce objawy uboczne: nudnoÊci (N=3), wymioty (N=3), zaparcie stolca (N=2) i wzmo˝ona potliwoÊç
(N=1), u ˝adnego z badanych nie pojawi∏y si´ objawy depresji oddechowej. TTS fentanyl okaza∏ si´ skutecznym i bezpiecz-
nym Êrodkiem w leczeniu bólu nowotworowego u pacjentów nie pobierajàcych wczeÊniej silnych opioidów.
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Introduction
The prevalence of pain has been estimated to occur in 30-
-50% patients undergoing oncological treatment and in
80-90% of palliative care patients [1]. WHO has introdu-
ced a 3-step analgesic ladder to give structure to the treat-
ment of cancer pain. Pharmacotherapy carried out ac-
cording to the WHO outlines is sufficient in 80-90% of
cancer pain [2]. Most of the patients (up to 70%) need
strong opioids to obtain good pain control [3, 4]. The
changes in blood concetration caused by oral, im, and iv
bolus administered drugs, may be accompanied by clinical
responses fluctuating between inadequate analgesia and
unwanted side effects. It is important to prevent and tre-
at the common side effects of opioids, especially nausea,
vomiting and constipation [5]. However there still exists
a need for an efficient, safe and convenient analgesic
agent for cancer- releted pain. Transdermal fentanyl intro-
duced in 1992 provides continuous opioid delivery wi-
thout the need for special equipment. The transcutanous
system provides constant release of the opioid for up to 72
hours [6-8]. The simplicity of TTS fentanyl administration
allows freedom to maintain a relatively normal lifestyle.
Some studies show that TTS fentanyl causes less side ef-
fects (especially constipation), than morphine [9]. Many
studies have been conducted to evaluate the safety and ef-
ficacy of TTS fentanyl in patients treated previosly with
other strong opioids [10, 11]. To provide adequate analge-
sia sometimes we have to move directly from step 1 to
step 3 of the analgesic ladder. This trial was designed to
investigate the efficacy and safety of TTS fentanyl as first
line treatment on stage III of the WHO ladder. in strong
opioid naive patients treated previously with up to the
maximal daily dose of tramadol.
Methods
The trial was performed in 6 oncology centres in Poland. The
main purpose was to investigate the clinical efficacy and safety of
TTS fentanyl given over the period of 28 days to strong opioid
naive patients, treated over the last 3 days prior to entering the
study with the maximal (400 mg) daily dose of tramadol. All of
them required strong opioids for pain management. 6 (8%)
patients suffered, only slight pain according to VRS, but were
included, because they demanded a better pain control. Sixty
six (92%) pts had moderate to very strong pain despite taking
400mg of tramadol a day.
The main objectives of this trial consist of the assessment
of: pain control, the performance status using the Karnofsky
and ECOG scale, the incidence and severity of adverse events
(nausea, vomiting, constipation, dyspnoea, cough) and the conve-
nience of the use of the patches. The severity of pain experien-
ced during both the day and night was evaluated by means of the
VAS (Visual Analoque Scale) and the VRS (Verbal Rating Sca-
le). An overall assessment of the pain treatment was performed
using 4-point scale (excellent, good, fair, poor) on day 1 and
day 28. As in most studies with patients with cancer pain, an
open design has been chosen for this study, and the recruitment
of patients was directed by the centres without randomisation.
Inclusion criteria were: histologically confirmed malignancy that
is not amenable to curative therapy at presentation, pain caused
by malignant disease, strong opioid naive patients, who require
analgesia according to step 3 of WHO analgesic ladder, previo-
us treatment with up to 400 mg of tramadol, age 18 years or
more, estimated survival of at least 3 months, ability to com-
municate, in women – adequate contraception in case of childbe-
aring age, the ability to read and sign informed consent. Exclu-
sion criteria were: a history of drug allergy to opioids, a history of
narcotic abuse prior to the diagnosis of cancer, active skin dise-
ase precluding application of the transdermal system, radiation
therapy for any painful sites within 7 days of entering the study,
participation in an investigational drug trial during 30 days prior
to the selection, changes in hormonal and/or cytostatic medi-
cation within the 7 days preceding entry into the study, serum bi-
lirubin level >2.0 mg/dl, serum creatinine level >2.0 mg/dl, any
co-existing medical condition that is likely to interfere with the
study procedures.
TTS fentanyl was started with the lowest available dose
(25 µg/h). A dose increase was allowed, if needed, every
third day. Due to the pharmacokinetics of the patch, suffi-
cient analgesic fentanyl concentration is reached within first
24 hours. For that reason, for the first 12-24 hours, the therapy of
tramadol should be continued with the same dose as previo-
usly. If, after 24 hours of TTS fentanyl, analgesia is not sufficient,
rescue medication (5 mg immediate-release oral morphine or
non-opioid drug) must be administered. The flow chart sho-
wing trial phases and timing of treatment and assessments is gi-
ven in Table I.
Results
Seventy two patients (45 men and 27 women) were inclu-
ded in the study. Mean age was 58 years (28-80 yrs.).
All patients reported cancer related pain. Primary
tumour localisations are listed in Table II. Losses from ob-
servation: 3 deaths caused by disease progression, 4 cases
of withdrawn consent (1 (SAEs) – day 2, nausea, vomiting,
dizziness; 1 – day 4, poor pain control; 1 – day 10, no re-
ason given; 1 – day 26, progressive weakness). One patient
stopped the treatment prematurely because of Serious
Adverse Experience (SAE) (doubtful relation to treat-
ment medication) and died 7 days later. Sixty four pa-
tients completed the study.
Tr a n s d e r m a l  f e n t a n y l  d o s e  a n d  a n a l g e s i c
e f f e c t
All patients started with the lowest available dose of fen-
tanyl (delivery rate 25 µg per hour). The dose had to be
increased in 46 patients. Dose stabilisation was observed
after on average 3 weeks of treatment. The maximum
dose reached 150 µg/hr on day 22.
The severity of pain experienced during the day and
the night was evaluated by means of VAS and VRS. If
analgesia was insufficient, patients were given a strong
opioid (5 mg of immediate-release oral morphine) or
non-opioid analgesic as rescue medication (Figure 2).
The most frequently used non-opioid drugs were: keto-
Key words: Cancer pain, transdermal fentanyl, tramadol, side effects
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profen (19 pts), naproxen sodium (1 pt), diclofenac (2
pts), metamizol sodium (2 pts), paracetamol (2 pts) and
papaverinum (2 pts).
At the end of the trial 45/64 (72%) pts experienced
no pain or slight pain, 15/64 (22%) pts had modera-
te pain and 4/64 (6%) pts strong or very strong pain
(VRS).
We noted an increase in the number of patients who
reported no pain or slight pain (VRS) on day 28 as com-
Table I. Flow chart
Visit nr 1 2 3 4
Visit day 1 2 16 28
Telephone contact 4 7 10 13 19 22 25
Performance status X X X
Concomitant medication X X X X
Determination of dose of TTS-fentanyl X X X X
Overall evaluation of pain treatment X X X X X X X X X X
Disease progression X
Evaluation of gastrointestinal disturbances X X X
Patient's preference X
Convenience of use of the patches X
Adverse experiences X
Rescue medication X X X X X X X X X X
VAS X X X X X X X X X X
Evaluation of dyspnoea and cough X X X
Patient (diary) Daily
Nausea and vomiting
VAS
VRS
Resque medication: (dose and freq./24h
Adverse events
Table II. Primary tumors
Primary tumors Number of 
patients
Melanoma 2
Head and neck ca 3
Adenocarcinoma (nonsp.) 2
Ovarian ca 4
Ovarian and pancreatic ca 1
Colon ca 6
Kidney ca 2
Lymphoma 1
Lung and bone metastases of unknow origin 1
Urinary bladder ca 1
Lung ca 32
Breast ca 9
Carcinoid 1
Retroperitoneal space ca 1
Cervix ca 4
Myeloma 1
Stomach ca 1
Figure 1. Average pain control (VAS) and mean transdermal fentanyl
dose during the trial
Figure 2. Average morphine consumption (rescue medication) on re-
spective days of the treatment
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pared to day 1 (see Table III). On day 28 we also noted
a significantly lower number of patients reporting mode-
rate, strong or very severe pain as compared to day 1.
Total assessment of the treatment at the end of the trial
was excellent in 15/64 (23%) pts, good in 36/64 (56%)
pts, fair in 9/64 (14%) pts and poor in 4/64 (6%) pts. Me-
an time needed to obtain good pain control (VAS
<30mm) was 7 days (Figure 1).
Table III. Pain assessment (VRS) on day 1 (baseline data) and day 28
VRS day 1 day 28
no pain or slight pain 6/72 (8%) 45/64 (72%)
moderate pain 27/72 (37%) 15/64 (22%)
strong or very strong 39/72 (55%) 4/64 (6%)
N a u s e a  a n d  v o m i t i n g
All patients were given metoclopramide (30 mg/daily) to
prevent nausea and vomiting. The severity of nausea was
evaluated once daily using a 4-point scale and was recor-
ded in the patients' diary each day. Absence of nausea
was reported by 53/72 (75%) patients, mild nausea by
15/72 (20%), moderate by 3/72 (4%) and severe by 1/72
(1%) at the beginning of the trial, versus (respectively)
50/64 (78%), 11/64 (17%), 3/64 (5%) and 0/64 (0%) on
day 28. Also the frequency of vomiting was recorded.
9/72 (13%) pts reported vomiting at the beginning and
only 2/64 (3%) on day 28.
D y s p n o e a  a n d  c o u g h
The severity of dyspnoea and cough was evaluated 
according to a 4-point scale and recorded in the patients'
diary each day. On the first day absence of dyspnoea 
reported 46/72 (64%) patients, mild dyspnoea 18/72
(25%), moderate 7/72 (10%), severe 1/72 (1%) and re-
spectively 42/64 (66%), 15/64 (23%), 5/64 (8%) and 2/64
(3%) on day 28. Cough was evaluated according to the 
same scale. On the first day absence of cough was repor-
ted by 47/72 (66%) patients, mild cough 19/72 (26%),
moderate 5/72 (7%), severe 1/72 (1%) and respectively
44/64 (69%), 16/64 (25%), 4/64 (6%) and 0/64 (0%) on
day 28.
G a s t r o i n t e s t i n a l  d i s t u r b a n c e s
The effects on the gastrointestinal tract were assessed by
evaluating the number, the consistency and the passage of
stools, the presence of abdominal pain and bloating, and
the use of laxatives at each visit.
18/72 patients (25%) reported abdominal pain on
day 1 and 10/64 (16%) on day 28. 23/72 patients (32%) re-
ported the use of laxatives on day 1 and 23/64 (37%) on
day 28. 37/64 (58%) patients described their stool as nor-
mal on day 28, as compared to 33/72 (46%) on day 1,
constipated stools were reported by 39/72 (54%) patients
on day 1 and 27/64 (42%) on day 28. The stool was “not
at all” or “a little of the time” difficult to pass for 28/72
(72%) patients on day 1 and 21/64 (78%) on day 28. Sto-
ols passed on less than 3 days/week on the first day were
reported by 17/72 (44%) patients versus 11/64 (41%) on
day 28.
G e n e r a l  c o n d i t i o n
The patients' general condition was recorded using the
Karnofsky performance status scale and the ECOG scale
before treatment (day 1), on day 16 and 28. The average
Karnofsky performance status score was 75 % before the
first medication and 74 % on day 28. According to ECOG
scale the patients' performance status was slightly worse at
the end of the treatment in comparison to the score obta-
ined at the beginning. This could have been due to disease
progression.
A d v e r s e  e v e n t s
During 28 days of this trial, 3 patients died as a consequ-
ence of advanced cancer. One patient stopped the treat-
ment prematurely, because of serious AEs (dyspnoea,
pain in the abdomen and in the chest) and died 7 days la-
ter. There was doubtful relation to the trial medication It
was a patient with inoperable, advanced pancreatic and
ovarian cancer. The patient reported increasing dyspnoea
and pain in her back on 25 day of Durogesic treatment.
She was admitted to the hospital the next day, due to se-
vere dyspnoea and pain in her chest and abdomen. The
X-ray of her chest revealed multiple metastases to the
lungs. Durogesic treatment was stopped on the day of
addmission, morphine and fentanyl iv were implemen-
ted instead. The patient died 7 days later due to cancer
progression.
One patient reported vomiting, dizziness, nausea
and another patient reported dyspnoea – these AEs were
possibly related to the trial medication.
The AEs regarded as probably, or very likely related
to transdermal fentanyl treatment were: nausea (N=3),
vomiting (N=3), constipation (N=2) and sweating (N=1)
and were observed in 7 patients.
Discussion
Most of the studies on transdermal fentanyl have included
strong opioid tolerant patients, and presented a change to
TTS fentanyl, after a stabilisation phase with either
a short acting strong opioid or intravenous fentanyl. Some
recent trials had included strong opioid naive patients
with insufficient pain control [12]. These studies have
shown, that both opioid naive and opioid tolerant pa-
tients with chronic cancer pain requiring strong opioids
may be treated with TTS fentanyl without a prior stabili-
sation phase. The need of a pain stabilisation phase with
morphine can therefore be questioned, and as a consequ-
ence of these studies patients with stabilised and unstabi-
lised pain, as well as opioid naive patients, could therefo-
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re be switched immediately to TTS fentanyl. A dose titra-
tion must, however, be performed under close monitoring.
In most studies, adequate relief of breaktrough pain was
obtained by adding oral morphine, as rescue medication.
In our trial rescue dose was relatively low (5 mg immedia-
te-release morphine), because we did not want the side ef-
fects of opioids interfere with TTS fentanyl side effects.
No pain or slight pain according to VRS was reached in
72% patients on day 28. Similar good effects of TTS fen-
tanyl used in 14 codeine treated, and 14 strong opioid
naive patients were noticed in a recent study [12]. Vie-
lvoye-Kerkmeer et al. reached a good and very good anal-
gesic effect in 68% of patients, constipation occurred in 3
(11%) patients. All patients in the study started with 25
ug/h TTS fentanyl, but the dose was sufficient in only 5
(18%) patients, and respectively in 18 (28%) in our study.
Rescue doses in our study were used more frequently du-
ring the few first days, and the highest average morphine
consumption was noticed on day 7, and then on day 25.
More than 66% of patients needed dose increasing. The
dose was increased to 50ug/h in 25 patients and to
75ug/h in 4 patients on day 4. The mean time needed to
obtain good pain control (VAS <30mm) was approxima-
tely 7 days. The initial dose of TTS fentanyl in our trial
was 25ug/h, no matter how strong the pain was. Higher in-
itial doses of TTS fentanyl in some cases, and higher re-
scue doses of morphine would probably shorten the time
before good pain control is obtained. According to Twy-
cross good pain control on morphine usually is obtained
after 3 to 5 days (at rest), and after 3 to 7 days (on move-
ment) (14).
Constipation existed in 39/72 (54%) patients on
tramadol (the first day of the trial) and in 27/64 (42%) on
the last day. Investigators observed only 2/64 (3%) ca-
ses of „de novo” occured constipation during the trial
and they reported them as AEs associated with the stu-
dy medication. Rescue doses of morphine could have
been responsible for constipation in some cases. Many
studies have proven that TTS fentanyl causes less con-
stipation then morphine [9, 10], which can be due to hi-
gher lipofility of fentanyl, which leads to faster penetra-
tion to the CNS and lower peripheral effects. We obse-
rved a decrease in nausea from 25% of patients on day 1
to 22% on day 28; and in vomiting – from 13% to 3%, re-
spectively.
Conclusion
A global assessment of the pain treatment with TTS
fentanyl was excellent in 15/64 (23%) pts, good in 36/64
(56%), fair in 9/64 (14%) and poor in 4/64 (6%) pts.
In this trial transdermal fentanyl proved to be a good
and safe analgesic agent for the first line treatment of
moderate to severe pain in strong opioid naive patients.
Clinically relevant respiratory depression was not found.
Constipation occurred in 2 (3%) patients. We did not ob-
serve serious AEs related to the trial medication. Overall,
the treatment was appreciated and well tolerated by the
patients. TTS fentanyl, (especially equivalent doses of
fentanyl and tramadol) in patients naive to strong opioids
needs further investigation.
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